GPR75 in obesity-driven cardiovascular and metabolic complications
GPR75 in obesity-driven cardiovascular and metabolic complications
批准号:
10633523
负责人:
Michal Laniado Schwartzman
金额:
$56.72万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-04-01 至 2027-02-28
关键词:
AdipocytesAdipose tissueAmino AcidsAndrogensAnimal ModelAttenuatedBindingBiologyC-terminalCOVID-19Cardiometabolic DiseaseCardiovascular DiseasesCardiovascular systemCell CommunicationCellsChromosomesClassificationCoculture TechniquesCommunicable DiseasesCouplesCytochrome P450DataDevelopmentDiabetes MellitusDietEndothelial CellsEndotheliumEpidemicFunctional disorderFundingG-Protein-Coupled ReceptorsGPR75 geneGenesGoalsHigh Fat DietHumanHydroxyeicosatetraenoic AcidsHyperglycemiaHyperinsulinismHypertensionHypertrophyImmunologicsImpairmentIndividualInflammatoryInsulin ReceptorInsulin ResistanceKnockout MiceLigandsLinkLiverLiver diseasesMapsMediatingMetabolicMetabolic DiseasesMetabolic syndromeMitochondriaMixed Function OxygenasesMonitorMorbidity - disease rateMusMuscle ContractionMyocardial InfarctionNonesterified Fatty AcidsObesityOrphanPathogenesisPhenotypePhosphorylationPlasmaPlayProductionProteinsRelaxationRisk FactorsRoleScienceSignal TransductionSkeletal MuscleSmooth MuscleStrokeSystemic TherapyTailTestingThinnessTissuesTransgenic MiceVariantVascular DiseasesVascular EndotheliumVisceral fatWeight GainWild Type Mouseantagonistblood glucose regulationcardiometabolismdriving forceendothelial dysfunctionexome sequencingexperimental studyfeedingglobal healthhuman modelhypertensiveinsulin receptor substrate 1 proteininsulin signalinglipid mediatorloss of functionnovelnovel therapeuticsobesity developmentoverexpressionpreventprogramsreceptor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract Summary
Obesity and the associated metabolic complications including metabolic syndrome and diabetes significantly contribute
to cardiovascular morbidities. The overall goal of this proposal is aimed at identifying cellular mechanisms that link
activation of the G-protein coupled receptor 75 (GPR75) to obesity-driven metabolic and cardiovascular complications. In
the last funding period, we provided strong evidence that GPR75 is the receptor to which 20-hydroxyeicosatetraenoic acid
(20-HETE), a vasoactive and pro-inflammatory lipid mediator, binds and through which it triggers its actions. 20-HETE
has been implicated in the development and progression of cardiovascular and metabolic diseases including hypertension,
stroke, myocardial infarction, diabetes and metabolic syndrome. Our recent studies clearly demonstrated that 20-HETE-
mediates vascular dysfunction in hypertension and diet-driven metabolic (e.g., insulin resistance) and cardiovascular (e.g.,
hypertension) complications through its pairing and activation of GPR75. The adipose tissue and the vascular endothelium
are key to the ensuing cardiometabolic disorders in obesity. They both express GPR75 and are prime targets for 20-HETE
bioactions. In the endothelium, 20-HETE, through its binding to GPR75, uncouples eNOS, induces ACE and activates the
NF-κB inflammatory program. 20-HETE stimulates adipocyte hypertrophy and interferes with adipocyte insulin signaling,
glucose homeostasis and mitochondria function. Endothelial dysfunction in hypertensive subjects and obesity in humans
and animal models are accompanied by several fold increases in circulating 20-HETE levels. Accordingly, it is reasonable
to assume that 20-HETE through its actions on the vascular endothelium and adipose tissue acts as a significant determinant
of obesity-driven cardiovascular and metabolic complications. Importantly, in a large-scale exome sequencing of ~600,000
individuals, we revealed that loss of function GPR75 variants are associated with leanness and protection from obesity
(Science, 2021). This finding, which has been validated in Gpr75 null mice (Science, 2021 and Preliminary Results),
compellingly implicates the 20-HETE-GPR75 pairing in the pathogenesis of obesity and its cardiometabolic complications
and calls for identification of the underlying mechanisms. Consequently, we hypothesized that 20-HETE-GPR75 pairing
promotes diet-driven cardiometabolic complications (e.g., hyperglycemia, insulin resistance, hypertension) by a
mechanism that impairs endothelial and adipocyte function. We further argue that 20-HETE-GPR75 pairing
governs a crosstalk between adipocytes and endothelial cells which contributes to cardiovascular and metabolic
complications in obesity. This hypothesis will be tested in three specific aims that assess the contribution of endothelial-
and adipocyte-specific Gpr75 to diet-driven obesity and examine potential mechanisms governing endothelial-adipocyte
crosstalk that are dependent on 20-HETE-GPR75 pairing.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of 20-HETE in Endothelial Dysfunction
-
批准号:7137827
-
项目类别:
-
资助金额:$32.73万
-
财政年份:2005
-
负责人:Michal Laniado Schwartzman
-
依托单位:
FUNCTION AND REGULATION OF CYTOCHROME P450 4A ISOFORMS
-
批准号:6796314
-
项目类别:
-
资助金额:$31.48万
-
财政年份:2003
-
负责人:Michal Laniado Schwartzman
-
依托单位:
FUNCTION AND REGULATION OF CYTOCHROME P450 4A ISOFORMS
-
批准号:6653343
-
项目类别:
-
资助金额:$31.48万
-
财政年份:2002
-
负责人:Michal Laniado Schwartzman
-
依托单位:
FUNCTION AND REGULATION OF CYTOCHROME P450 4A ISOFORMS
-
批准号:6578854
-
项目类别:
-
资助金额:$31.48万
-
财政年份:2001
-
负责人:Michal Laniado Schwartzman
-
依托单位:
FUNCTION AND REGULATION OF CYTOCHROME P450 4A ISOFORMS
-
批准号:6500478
-
项目类别:
-
资助金额:$31.48万
-
财政年份:2001
-
负责人:Michal Laniado Schwartzman
-
依托单位:
FUNCTION AND REGULATION OF CYTOCHROME P450 4A ISOFORMS
-
批准号:6353524
-
项目类别:
-
资助金额:$31.48万
-
财政年份:2000
-
负责人:Michal Laniado Schwartzman
-
依托单位:
ARACHIDONATE OMEGA 1 HYDROXYLATION IN HYPERTENSION
-
批准号:6202241
-
项目类别:
-
资助金额:$24.35万
-
财政年份:1999
-
负责人:Michal Laniado Schwartzman
-
依托单位:
ARACHIDONATE OMEGA 1 HYDROXYLATION IN HYPERTENSION
-
批准号:6109762
-
项目类别:
-
资助金额:$24.35万
-
财政年份:1998
-
负责人:Michal Laniado Schwartzman
-
依托单位:
HORMONAL REGULATION OF BLOOD PRESSURE
-
批准号:8256755
-
项目类别:
-
资助金额:$228.57万
-
财政年份:1997
-
负责人:Michal Laniado Schwartzman
-
依托单位:
HORMONAL REGULATION OF BLOOD PRESSURE
-
批准号:8447431
-
项目类别:
-
资助金额:$218.16万
-
财政年份:1997
-
负责人:Michal Laniado Schwartzman
-
依托单位:
HORMONAL REGULATION OF BLOOD PRESSURE
-
批准号:8827392
-
项目类别:
-
资助金额:$220.11万
-
财政年份:1997
-
负责人:Michal Laniado Schwartzman
-
依托单位:
HORMONAL REGULATION OF BLOOD PRESSURE
-
批准号:8644831
-
项目类别:
-
资助金额:$225.15万
-
财政年份:1997
-
负责人:Michal Laniado Schwartzman
-
依托单位:
ARACHIDONATE OMEGA 1 HYDROXYLATION IN HYPERTENSION
-
批准号:6241862
-
项目类别:
-
资助金额:$23.54万
-
财政年份:1997
-
负责人:Michal Laniado Schwartzman
-
依托单位:
Hormonal Regulation of Blood Pressure
-
批准号:7480956
-
项目类别:
-
资助金额:$235.28万
-
财政年份:1997
-
负责人:Michal Laniado Schwartzman
-
依托单位:
HORMONAL REGULATION OF BLOOD PRESSURE
-
批准号:8079198
-
项目类别:
-
资助金额:$224.82万
-
财政年份:1997
-
负责人:Michal Laniado Schwartzman
-
依托单位:
Hormonal Regulation of Blood Pressure
-
批准号:7674730
-
项目类别:
-
资助金额:$246.49万
-
财政年份:1997
-
负责人:Michal Laniado Schwartzman
-
依托单位:
HORMONAL REGULATION OF BLOOD PRESSURE
-
批准号:8392082
-
项目类别:
-
资助金额:$1.92万
-
财政年份:1997
-
负责人:Michal Laniado Schwartzman
-
依托单位:
CORNEAL ARACHIDONATE METABOLITES VIA CYTOCHROME P450
-
批准号:2160376
-
项目类别:
-
资助金额:$28.4万
-
财政年份:1987
-
负责人:Michal Laniado Schwartzman
-
依托单位:
CORNEAL ARACHIDONATE METABOLITES VIA CYTOCHROME P450
-
批准号:2710922
-
项目类别:
-
资助金额:$30.72万
-
财政年份:1987
-
负责人:Michal Laniado Schwartzman
-
依托单位:
CORNEAL ARACHIDONATE METABOLITES VIA CYTOCHROME P450
-
批准号:3262758
-
项目类别:
-
资助金额:$10.17万
-
财政年份:1987
-
负责人:Michal Laniado Schwartzman
-
依托单位:
海外基金